Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death - Drugs
- ️Anderson, Ian M.
- ️Sun Sep 16 2012
Leestma JE, Koenig KL. Sudden death and phenothiazines. Arch Gen Psychiatry 1968; 18: 137–48
Kelly HG, Fay JE, Laverty SG, et al. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report on two fatalities with electrocardiographic abnormalities. Can Med Assoc J 1963; 89: 546–54
Hollister LE, Koesk JC. Sudden death during treatment with phenothiazine derivatives. JAMA 1965; 192: 1035–8
Huston JR, Bell GE. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram. JAMA 1966; 198: 134–8
Simpson GM, Davis J, Jefferson JW, et al. Sudden deaths in psychiatric patients: The role of neuroleptic drugs. Washington DC: American Psychiatric Association Task Force; 1987. Report no. 27
Royal College of Psychiatrists. The association between anti-psychotic drugs and sudden death. Report of the Working Group of the Royal College of Psychiatrists’ Psychopharmacology Sub-Group. London: Royal College of Psychiatrists; 1997. Council Report No. CR57
Haverkamp W, Breithardt G, Camm J, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Eur Heart J 2000; 21(15): 1216–31. Published simultaneously in Cardiovasc Res 2000; 47 (2): 219–33
FDA. Psychopharmacological Drugs Advisory Committee. 19 July, 2000. Briefing Document for Zeldox Capsules (zipriasone hydrochloride) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf [Accessed 2002 Jun 24]
Roden DM, Woosley RL, Primm PK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986; 111: 1088–93
Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17–26
Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2: 806–17
Bauman JL, Bauernfeind RA, Hoff JV, et al. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J 1984; 107: 425–30
Hohnnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks and management. Am J Cardiol 1997; 80: G82–9
Haverkamp W, Martinez RA, Hief C, et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 1997; 30: 487–95
Lehmann MH, Hardy S, Archibald D, et al. Sex differences in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94: 2535–41
Waldo AL, Camm AJ, deRuyter H, et al. Effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet 1996; 348(9019): 7–12
Committee on Safety of Medicines-Medicines Control Agency. Suspension of availability of sertindole (serdolect). Current Problems in Pharmacovigilance 1999; 25: 1
Committee on Safety of Medicines-Medicines Control Agency. QT interval prolongation with antipsychotics. Current Problems in Pharmacovigilance 2001; 27: 4
Committee on Safety of Medicines-Medicines Control Agency. Cardiac arrhythmias with pimozide (Orap). Current Problems in Pharmacovigilance 1995; 21: 1
Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502–8
Jusic N, Lader M. Post-Mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 1994; 165: 787–91
Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000; 20(3): 317–24
Mehtonen OP, Aranko K, Malkonen L, et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84: 58–64
Reilly JG, Ayis A, Ferner IN, et al. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002; 180: 515–22
Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161–7
Cancro R, Wilder R. A mechanism of sudden death in chlorpromazine therapy. Am J Psychiatry 1970; 127: 368–71
Weiner WJ, Goetz CG, Nausieda PA, et al. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978; 88: 327–31
Modestin J, Krapf R, Boker W A fatality during haloperidol treatment: mechanism of sudden death. Am J Psychiatry 1981; 138: 1661–17
Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–5
Hoehns JD, Fouts MM, Kelly MW, et al. Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother 2001; 35: 862–6
Committee For Proprietary Medicinal Products (CPMP) Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London: 1997 Dec
Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation. Implications for drug approval and labelling. Drug Saf 2001; 24: 323–51
Higham PD, Campbell RWE QT dispersion. Br Heart J 1994; 71: 508–10
Ong JJ, Sarma JS, Venkataraman K, et al. Circadian rhythmicity of heart rate and QTc interval in diabetic autonomic neuropathy: implications for the mechanism of sudden death. Am Heart J 1993; 125: 744–52
Nagy D, DeMeersman R, Gallagher D, et al. QTc interval (cardiac repolarisation): Lengthening after meals. Obes Res 1997; 5: 531–7
Carella MJ, Mantz SL, Rovner DR, et al. Obesity, adiposity, and lengthening of the QT interval: improvement after loss. Int J Obes Relat Metab Disord 1996; 20: 938–42
El-Gamal A, Gallagher D, Nawras A, et al. Effects of obesity on QT, RR, and QTc intervals. Am J Cardiol 1995; 75: 956–9
Stramba-Badiale M, Locati EH, Martinelli A, et al. Gender and the relationship between ventricular repolarisation and cardiac cycle length during 24-hour Holter recordings. Eur Heart J 1997; 18: 1000–6
Funck-Bretano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72: B17–22
De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000; 56: 1–18
Bril A, Gout B, Bonhomme M, et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrthymic risk: experimental profile of BRL- 32872. J Pharmacol Exp Ther 1996; 276: 637–46
De Cicco M, Marcor F, Robieux I, et al. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit. Crit Care Med 1999; 27: 332–9
Suessbrich H, Schonherr R, Heinemann SH, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997; 120: 968–74
Drolet B, Zhang S, Deschenes D, et al. Droperidol lengthens cardiac repolarisation due to block of the rapid component of the delayed rectified potassium current. J Cardiovasc Electrophysiol 1999; 10: 1597–604
Drolet B, Vincent F, Rail J, et al. Thioridazine lengthens repolarisation of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 1999; 288: 1261–8
Kang J, Wang L, Cai F, et al. High affinity blockade of the HERG cardiac K+ channel by the neuroleptic pimozide. Eur J Pharmacol 2000; 392: 137–40
Rampe D, Murawsky MK, Grau J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998; 286: 788–93
Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996; 93: 311–3
Reilly JG, Ayes SA, Ferrier IN, et al. QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 335: 1048–52
FDA Psychopharmacological Drugs Advisory Committee. 19 July, 2000. Background on Zeldox (ziprasidone hydrochloride capsules) Pfizer, Inc [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1b.pdf [Accessed 2002 Jun 24]
Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33: 199–204
Hulisz DT, Dasa SL, Black LD, et al. Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 1994; 14: 239–45
Paoloni P, Ciliberti D, Blasi N, et al. Iatrogenic torsade de pointes induced by thioridazine. Minerva Cardioangiol 1992; 40: 245–9
Bastecky J, Kvasnicka J, Vortel J, et al. Suicidal ingestion of thioridazine as a cause of severe impairment of heart rhythmpolymorphic ventricular tachycardia. Cesk Psychiatr 1990; 86: 264–8
Flugemlman MY, Tal A, Pollock S, et al. Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 1985; 46: 290–1
Kiriike N, Maeda Y, Nishiwaki S, et al. Iatrogenic torsade de pointes induced by thioridazine. Biological Psychiatry 22: 99–103
Kirchner V, Kelly CA, Harvey RJ. A systematic review of the evidence for the safety and efficacy of thioridazine in dementia. Available in The Cochrane Library [database on disk and CD ROM]. Updated The Cochrane Collaboration; issue 4. Oxford: Update Software, 1998
Dear Healthcare Professional letter. Thioridazine: restricted indications and new warnings on cardiotoxicity. London: Committee on Safety of Medicines, 2000 Dec 11
Dear Healthcare Professional letter. Thioridazine. New Jersey: Novartis Pharmaceuticals Corporation, 2000 Jul 7
Dear Healthcare Professional letter. Mesoridazine. New Jersey: Novartis Pharmaceuticals Corporation, 2000 Sep 22
Association of the British Pharmaceutical Industry (ABPI) Medicines Compendium 2002. London: Datapharm Communications Limited, 2002
Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 1987; 144: 673–5
British Medical Association and Royal Pharmaceutical Society of Great Britain. Antipsychotic Drugs. Section 4.2.1. London: British National Formulary, 2002 Mar: 174–84
Lischke V, Behne M, Doelken P, et al. Droperidol causes dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79: 983–6
Fayer SA. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol [letter]. J Clin Psychopharmacol 1986; 6: 375–6
Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperdiol-induced torsades de pointes. Chest 1990; 98: 482–4
Hunt N, Stern TA. The association between intravenous haloperdiol and torsades de pointes: three cases and a literature review. Psychosomatics 1995; 36: 541–9
Hernderson RA, Lane S, Henry JA. Life-threatening ventricular arrhythmia (torsade de pointes) after haloperdiol overdose. Hum Exp Toxiciol 1991; 10: 59–62
Sharma ND, Rosman HS, Padhi ID, et al. Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238–40
Ochiai H, Kashiwagi M, Usui T, et al. Torsade de pointes with T wave alternans in a patients receiving moderate dose of chlorpromazine: a report of a case [in Japanese]. Kokyu To Junkan 1990; 38: 819–22
Lande G, Drouin E, Gauthier C, et al. Arrhythmogenic effects of sultopride chlorhydrate: clinical and cellular electrophysiological correlation [in French]. Ann Fr Anesth Reanim 1992; 11: 629–35
Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782–91
Serdolect (sertindole) [product monograph], revised. Copenhagen, Denmark: Lundbeck, 1997 Jan: 39–43
Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The sertindole study group. Psychopharmacol Bull 1998; 34: 61–9
Fritze J, Bandelow B. The QT interval and the atypical antipsychotic, sertindole. Int J Psych Clin Pract 1998; 2: 265–73
Pfizer. Geodon (Ziprasidone hydrochloride) [summary of product characteristics]. Pfizer US Pharmaceuticals. Issued 2001 Feb
Yerrabolu M, Prabhudesai S, Tawam M, et al. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis 2000; 2: 10–2
Lo Vecchio F, Hamilton RJ, Hoffman RJ. Risperidone overdose. Am J Emerg Med 2000; 14: 95–6
Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997; 31: 867–70
Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61: 441–6
Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 2000; 20: 325–7
Product Monograph for Zoleptil (zotepine). Knoll AG. Germany 1999, 37
Czekalla J, Beasley CM, Dellva MA, et al. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 2001; 62: 191–8
Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group. Multiple fixed doses of ‘seroquel’ (quetiapine) in patients with exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46
Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole and clozapine. J Clin Psychopharmacol 2001; 21: 8–13
Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625–33
Sudden Arrhythmia Death Syndromes (S ADS) Foundation. An overview of the inherited long QT syndrome. Available from URL: http://www.sads.org/LQTS.html [Accessed 2002 Jun 24]
Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001; 110: 385–98
Houltz B, Darpo B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 124: 663–8
Jackman WNM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovascular Dis 1988; 31: 115–72
Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug induced QT prolongation and life threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 6: 691–6
Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97: 100613–8
Clancy CE, Rudy Y Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature 1999; 400: 566–9
Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: Predicting torsade de pointes. Pacing Clin Electrophysiol 1998; 21: 1029–34
Tomasselli GF, Marban E. Electrophysiological remodelling in hypertrophy and heart failure. Cardiovasc Res 1999; 42: 270–83
Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000 Sep; 23(3): 215–28
Committee on Safety of Medicines. Cardiotoxic effects of pimozide. Current problems in Pharmacovigilance 1990; 29: 11–2,35
Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590–7
Drici MD, Knollmann BC, Wang WX, et al. Cardiac actions of erythromycin: influence of female sex. JAMA 1998; 280: 1774–6
Hillis WS, Mclntyre PD, Maclean J, et al. S udden death in sport. BMJ 1994; 309: 657–60
Engel GL. Sudden and rapid death during psychological stress: folklore or folk wisdom? Ann Intern Med 1971; 74: 771–82
Malik MA. Emotional distress as a precipitating factor in sudden deaths due to coronary insufficiency. J Forensic Sci 1973; 18: 47–52
Kumar A. Sudden unexplained death in a psychiatric patient — a case report: the role of phenothiazines and physical restraint. Med Sci Law 1997; 37: 170–5
Banerjee S, Bingley W, Murphy E. Deaths of detained patients: a review of reports to the Mental Health Act Commission. London: Mental Health Foundation, 1995
Koide T, Ozeki K, Kaihara S, et al. Etiology of QT prolongation and T wave changes in chronic alcoholism. Jpn Heart J 1981; 22: 151–66
Yokoyama A, Ishii H, Takagi T, et al. Prolonged QT interval in alcoholic autonomie nervous dysfunction. Alcohol Clin Exp Res 1992; 16: 1090–2
Perera R, Kraebber A, Schwartz MJ. Prolonged QT interval and cocaine use. J Electrocardiol 1997; 30: 337–9
Gamouras GA, Monir G, Plunkitt K, et al. Cocaine abuse: repolarisation abnormalities and ventricular arrhythmias. Am J Med Sci 2000; 320: 9–12
Karch SB. Cardiac arrest in cocaine users. Am J Emerg Med 1996; 14: 79–81
Wetli CV, Fishbain DA. Cocaine-induced psychosis and sudden death in recreational cocaine users. J Forensic Sci 1985; 30: 873–80
Lange R, Cigarroa R, Flores E, et al. Cocaine-induced coronaryartery vasoconstriction. N Engl J Med 1989: 321; 1557–62
Dorson PG, Crismon ML. Chlorpromazine accumulation and sudden death in a patient with renal insufficiency. Drug Intell Clin Pharm 1988; 22: 776–8
Kroemer HK, Eichelbaum M. ‘It’s the genes, stupid’. Molecular bases and clinical consequences of genetic cytochrome P4502D6 polymorphism. Life Sci 1995; 56: 2285–98
Honig PK, Wortham DC, Zamani K, et al. Tefenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–8
Van Haarst AD, van’t Klooster GAE, van Gerven JMA, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998; 66: 542–6
Kivisto KT, Lilja JJ, Backman JT, et al. Repeated consumption of grapefruit juice considerably increases plasma concentration of cisapride. Clin Pharmacol Ther 1999; 66: 448–53
Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698–703
Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6
Herrmann HC, Kaplan LM, Bierer BE. Q-T prolongation and torsade de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983; 51: 904–6
Heiman EM. Cardiac toxicity with thioridazine-tricyclic antidepressant combination. J Nerv Ment Dis 1977; 165: 139–43
Swanson JR, Jones GR, Krasselt W, et al. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci 1997; 42: 3335–339
Coupland N, Wilson S, Nutt D. Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 1997; 11: 83–92
Edwards JG, Goldie A, Papayanni-Papasthatis S. Effects of paroxetine on the electrocardiogram. Psychopharmacology 1989; 97: 96–8
Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997; 17: 15–21
Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23: 435–40
Eefurth A, Loew M, Dobmeier P, et al. ECG changes after paroxetine. 3 case reports [in German]. Nervenarzt 1998; 69: 629–31
Meuleman C, Jourdain P, Bellorinin M, et al. Citalopram and torsade de pointes. A case report [in French]. Arch Mal Coeur Vaiss 2001; 94: 1021–4
Waddington JL, Youssef HA, Kinsella A. Mortality in Schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9
Yap YG, Camm J. Risk of torsade de pointes with non-cardiac drugs. BMJ 2000; 320: 1158–9
Cavuto NJ, Woosley RL, Sale M, et al. Pharmacies and prevention of potentially fatal drug interactions. JAMA 1996; 275: 1086–7
Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996; 275: 1339–41
Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284: 3036–9
Warner JP, Gledhill JA, Connell F, et al. How well do psychiatric trainees interpret electrocardiographs. A cross-sectional survey. Psychiatr Bull R Coll Psychiatr 1996; 20: 651–2
Thompson C. Consensus statement: the use of high-dose antipsychotic medication. Br J Psychiatry 1994; 164: 448–58
Simpson D, Anderson I. Rapid tranquillisation: a questionnaire survey of practice. Psychiatr Bull R Coll Psychiatr 1996; 20: 149–52
Pilowsky LS, Ring H, Shine PJ, et al. Rapid tranquillisation: a survey of emergency prescribing in a general psychiatric hospital. Br J Psychiatry 1992; 160: 831–5
Haw C, Stubbs J. New BNF maximum recommended dose for haloperidol. Psychiatr Bull R Coll Psychiatr 2001; 25: 120–1
Appleby L, Thomas S, Ferrier N, et al. Sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2000; 176: 405–6